002940 昂利康
已收盘 07-02 15:00:00
资讯
新帖
简况
昂利康最新公告：向特定对象发行股票申请获深交所审核通过
证券之星 · 07-01 20:20
昂利康最新公告：向特定对象发行股票申请获深交所审核通过
7月1日昂利康涨10.00%，国泰海通新锐量化选股混合A基金重仓该股
证券之星 · 07-01 16:49
7月1日昂利康涨10.00%，国泰海通新锐量化选股混合A基金重仓该股
7月1日昂利康（002940）涨停分析：过评获批、GMP进展、专精特新驱动
证券之星 · 07-01 15:38
7月1日昂利康（002940）涨停分析：过评获批、GMP进展、专精特新驱动
异动快报：昂利康（002940）7月1日14点4分触及涨停板
证券之星 · 07-01 14:06
异动快报：昂利康（002940）7月1日14点4分触及涨停板
股市必读：新发布《浙江昂利康制药股份有限公司与东方证券股份有限公司关于浙江昂利康制药股份有限公司申请向特定对象发行股票的审核问询函的回复》
证券之星 · 07-01 01:49
股市必读：新发布《浙江昂利康制药股份有限公司与东方证券股份有限公司关于浙江昂利康制药股份有限公司申请向特定对象发行股票的审核问询函的回复》
6月26日昂利康跌6.06%，国泰海通新锐量化选股混合A基金重仓该股
证券之星 · 06-26
6月26日昂利康跌6.06%，国泰海通新锐量化选股混合A基金重仓该股
6月23日昂利康涨5.73%，国泰海通新锐量化选股混合A基金重仓该股
证券之星 · 06-23
6月23日昂利康涨5.73%，国泰海通新锐量化选股混合A基金重仓该股
昂利康：ALK-N001项目临床研究正按计划推进中
证券之星 · 06-11
昂利康：ALK-N001项目临床研究正按计划推进中
昂利康(002940.SZ)获得依托考昔片药品注册证书
智通财经 · 06-09
昂利康(002940.SZ)获得依托考昔片药品注册证书
6月8日昂利康跌5.70%，国泰海通新锐量化选股混合A基金重仓该股
证券之星 · 06-08
6月8日昂利康跌5.70%，国泰海通新锐量化选股混合A基金重仓该股
6月5日昂利康跌9.83%，国泰海通新锐量化选股混合A基金重仓该股
证券之星 · 06-05
6月5日昂利康跌9.83%，国泰海通新锐量化选股混合A基金重仓该股
昂利康（002940）披露获得化学原料药上市申请批准通知书，6月2日股价下跌3.46%
证券之星 · 06-02
昂利康（002940）披露获得化学原料药上市申请批准通知书，6月2日股价下跌3.46%
昂利康(002940.SZ)：阿莫西林与氨苄西林获批上市
智通财经 · 06-02
昂利康(002940.SZ)：阿莫西林与氨苄西林获批上市
昂利康(002940.SZ)：子公司异氟烷获得药品注册证书
智通财经 · 06-01
昂利康(002940.SZ)：子公司异氟烷获得药品注册证书
昂利康（002940）披露2025年度股东会决议公告，5月29日股价下跌1.41%
证券之星 · 05-29
昂利康（002940）披露2025年度股东会决议公告，5月29日股价下跌1.41%
昂利康(002940.SZ)：氟伐他汀钠缓释片获得药品注册证书
智通财经 · 05-29
昂利康(002940.SZ)：氟伐他汀钠缓释片获得药品注册证书
股市必读：新发布《浙江昂利康制药股份有限公司与东方证券股份有限公司关于浙江昂利康制药股份有限公司申请向特定对象发行股票的审核问询函的回复》
证券之星 · 05-28
股市必读：新发布《浙江昂利康制药股份有限公司与东方证券股份有限公司关于浙江昂利康制药股份有限公司申请向特定对象发行股票的审核问询函的回复》
昂利康（002940）披露2025年度向特定对象发行A股股票预案（二次修订稿），5月27日股价上涨2.56%
证券之星 · 05-27
昂利康（002940）披露2025年度向特定对象发行A股股票预案（二次修订稿），5月27日股价上涨2.56%
昂利康（002940）披露股票交易异常波动公告，5月25日股价下跌10.0%
证券之星 · 05-25
昂利康（002940）披露股票交易异常波动公告，5月25日股价下跌10.0%
昂利康最新公告：公司不涉及光芯片等半导体领域的业务和投资行为
证券之星 · 05-25
昂利康最新公告：公司不涉及光芯片等半导体领域的业务和投资行为
加载更多
公司概况
公司名称：
浙江昂利康制药股份有限公司
所属行业：
医药制造业
上市日期：
2018-10-23
主营业务：
浙江昂利康制药股份有限公司的主营业务是化学原料药、化学制剂及特色中间体系列产品的研发、生产和销售。公司的主要产品是抗感染类、心血管类、泌尿系统类（肾病类）、麻醉疼痛类、抗雄性激素类。
发行价格：
23.07
{"stockData":{"symbol":"002940","market":"SZ","secType":"STK","nameCN":"昂利康","latestPrice":29.06,"timestamp":1782975801000,"preClose":29.05,"halted":0,"volume":24620502,"delay":0,"changeRate":0.0003,"floatShares":185000000,"shares":202000000,"eps":0.6306,"marketStatus":"已收盘","change":0.01,"latestTime":"07-02 15:00:00","open":30,"high":30.33,"low":28.6,"amount":724000000,"amplitude":0.0596,"askPrice":29.07,"askSize":36,"bidPrice":29.06,"bidSize":511,"shortable":0,"etf":0,"ttmEps":0.6306,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783042200000},"marketStatusCode":5,"adr":0,"adjPreClose":29.05,"symbolType":"stock","openAndCloseTimeList":[[1782955800000,1782963000000],[1782968400000,1782975600000]],"highLimit":31.96,"lowLimit":26.15,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":201728186,"isCdr":false,"pbRate":3.56,"roa":"--","peRate":46.083095,"roe":"1.08%","epsLYR":0.62,"committee":0.403882,"marketValue":5862000000,"turnoverRate":0.1329,"status":0,"floatMarketCap":5384000000},"requestUrl":"/m/hq/s/002940/","defaultTab":"news","newsList":[{"id":"2648708548","title":"昂利康最新公告：向特定对象发行股票申请获深交所审核通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2648708548","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648708548?lang=zh_cn&edition=full","pubTime":"2026-07-01 20:20","pubTimestamp":1782908406,"startTime":"0","endTime":"0","summary":"昂利康(002940.SZ)公告称，公司于2026年7月1日收到深交所上市审核中心出具的审核中心意见告知函，认为公司符合发行条件、上市条件和信息披露要求，后续将按规定报证监会履行注册程序。该事项尚需证监会同意注册后方可实施，存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100039951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648451694","title":"7月1日昂利康涨10.00%，国泰海通新锐量化选股混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648451694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648451694?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:49","pubTimestamp":1782895778,"startTime":"0","endTime":"0","summary":"证券之星消息，7月1日昂利康涨10.00%，收盘报29.05元，换手率11.42%，成交量21.15万手，成交额5.91亿元。国泰海通新锐量化选股混合A目前规模为0.2亿元，最新净值1.4761，较上一交易日上涨2.85%。国泰海通新锐量化选股混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1147","BK1564","02611","601211","BK0239","BK0201","002940","BK0028","BK0184","BK0188","BK0183","BK0276","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648513512","title":"7月1日昂利康（002940）涨停分析：过评获批、GMP进展、专精特新驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2648513512","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648513512?lang=zh_cn&edition=full","pubTime":"2026-07-01 15:38","pubTimestamp":1782891491,"startTime":"0","endTime":"0","summary":"证券之星消息，昂利康7月1日涨停收盘，收盘价29.05元。该股于13点7分涨停，9次打开涨停，截止收盘封单资金为3256.21万元，占其流通市值0.6%。7月1日昂利康涨停的可能因素有：公司于6月28日公告盐酸阿罗洛尔片通过仿制药一致性评价，该品种为高血压一线用药，市场空间明确；同期公告控股子公司浙江昂利泰获原料药GMP符合性检查通知，强化产业链自主可控预期；此外，公司近期入选浙江省‘专精特新’中小企业名单，政策支持信号增强。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100024770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940","399267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648559749","title":"异动快报：昂利康（002940）7月1日14点4分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2648559749","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648559749?lang=zh_cn&edition=full","pubTime":"2026-07-01 14:06","pubTimestamp":1782885989,"startTime":"0","endTime":"0","summary":"证券之星7月1日盘中消息，14点4分昂利康（002940）触及涨停板。其所属行业化学制药目前上涨。领涨股为汇宇制药。该股为创新药，化学原料药，医药概念热股，当日创新药概念上涨4.93%，化学原料药概念上涨4.58%，医药概念上涨4.26%。6月30日的资金流向数据方面，主力资金净流出2145.29万元，占总成交额6.89%，游资资金净流出2294.17万元，占总成交额7.36%，散户资金净流入4439.46万元，占总成交额14.25%。近5日资金流向一览见下表：昂利康主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100023316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648654755","title":"股市必读：新发布《浙江昂利康制药股份有限公司与东方证券股份有限公司关于浙江昂利康制药股份有限公司申请向特定对象发行股票的审核问询函的回复》","url":"https://stock-news.laohu8.com/highlight/detail?id=2648654755","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648654755?lang=zh_cn&edition=full","pubTime":"2026-07-01 01:49","pubTimestamp":1782841751,"startTime":"0","endTime":"0","summary":"浙江昂利康制药股份有限公司与东方证券股份有限公司关于浙江昂利康制药股份有限公司申请向特定对象发行股票的审核问询函的回复公司就深交所审核问询函所涉扣非归母净利润变动、主营业务毛利率下降、境外收入增长、研发支出、商誉减值风险、财务性投资及资质证书续期等问题作出详细说明，并补充披露相关风险；中介机构已核查并发表意见。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100001023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK1574","01477","BK1147","600958","BK0239","03958","BK0183","BK0276","BK0188","BK0012","BK1564","BK1191","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646857358","title":"6月26日昂利康跌6.06%，国泰海通新锐量化选股混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646857358","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646857358?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:53","pubTimestamp":1782464038,"startTime":"0","endTime":"0","summary":"证券之星消息，6月26日昂利康跌6.06%创60日新低，收盘报26.05元，换手率7.37%，成交量13.66万手，成交额3.61亿元。重仓昂利康的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为国泰海通资管的国泰海通新锐量化选股混合A。国泰海通新锐量化选股混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600030676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1564","BK0188","BK1147","BK0276","02611","BK0184","002940","BK0201","BK0239","601211","BK0012","BK0183","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645881603","title":"6月23日昂利康涨5.73%，国泰海通新锐量化选股混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645881603","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645881603?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:37","pubTimestamp":1782203852,"startTime":"0","endTime":"0","summary":"证券之星消息，6月23日昂利康涨5.73%，收盘报30.1元，换手率14.34%，成交量26.57万手，成交额7.98亿元。国泰海通新锐量化选股混合A目前规模为0.2亿元，最新净值1.5085，较上一交易日上涨0.48%。国泰海通新锐量化选股混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601211","02611","BK0201","BK0184","BK0239","BK0183","BK0188","BK1147","BK1564","BK0276","BK0012","BK0028","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642535282","title":"昂利康：ALK-N001项目临床研究正按计划推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2642535282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642535282?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:51","pubTimestamp":1781182307,"startTime":"0","endTime":"0","summary":"证券之星消息，昂利康06月10日在投资者关系平台上答复投资者关心的问题。投资者提问：公司ALK-N001旧临床试验于2026年4月6日主动暂停，原定入组90例、仅入组16例即终止。另外，新开展的CTR20261097临床试验相比旧方案，具体做了哪些核心调整？昂利康回复：您好，公司ALK-N001项目临床研究正按计划推进中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100036048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642463067","title":"昂利康(002940.SZ)获得依托考昔片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2642463067","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642463067?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:54","pubTimestamp":1780995252,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 昂利康(002940.SZ)发布公告，近日，公司收到国家药品监督管理局(以下简称“国家药监局”)签发的依托考昔片《药品注册证书》，依托考昔片适用于治疗骨关节炎急性期和慢性期的症状和体征、急性痛风性关节炎和原发性痛经。本次公司获得依托考昔片药品注册证书，将进一步丰富公司的仿制药产品管线，增强公司的综合竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641100883","title":"6月8日昂利康跌5.70%，国泰海通新锐量化选股混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641100883","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641100883?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:56","pubTimestamp":1780908975,"startTime":"0","endTime":"0","summary":"重仓昂利康的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为国泰海通资管的国泰海通新锐量化选股混合A。国泰海通新锐量化选股混合A目前规模为0.2亿元，最新净值1.4268，较上一交易日上涨0.13%。国泰海通新锐量化选股混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800022506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02611","BK0028","BK0188","BK0239","BK0012","601211","BK0276","BK1147","BK0184","BK0183","002940","BK0201","BK1564"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641116504","title":"6月5日昂利康跌9.83%，国泰海通新锐量化选股混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641116504","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641116504?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:42","pubTimestamp":1780648963,"startTime":"0","endTime":"0","summary":"证券之星消息，6月5日昂利康跌9.83%，收盘报31.75元，换手率15.47%，成交量28.67万手，成交额9.39亿元。国泰海通新锐量化选股混合A目前规模为0.2亿元，最新净值1.4249，较上一交易日下跌0.13%。国泰海通新锐量化选股混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0276","BK0188","BK0183","601211","BK0184","BK0012","BK0239","002940","BK0201","02611","BK1564","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640994954","title":"昂利康（002940）披露获得化学原料药上市申请批准通知书，6月2日股价下跌3.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640994954","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640994954?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:13","pubTimestamp":1780409632,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，昂利康报收于33.18元，较前一交易日下跌3.46%，最新总市值为66.93亿元。该股当日开盘34.96元，最高34.98元，最低32.61元，成交额达4.27亿元，换手率为6.91%。近日，浙江昂利康制药股份有限公司收到国家药品监督管理局签发的《化学原料药上市申请批准通知书》，阿莫西林和氨苄西林原料药获批注册。目前国内已有包括公司在内的多家企业取得阿莫西林和氨苄西林原料药A状态登记，市场竞争较为激烈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200047156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640919357","title":"昂利康(002940.SZ)：阿莫西林与氨苄西林获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2640919357","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640919357?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:12","pubTimestamp":1780391566,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昂利康 发布公告，近日，公司收到国家药品监督管理局签发的《化学原料药上市申请批准通知书》。公司分别于2024年12月、2025年1月递交了阿莫西林原料药、氨苄西林原料药的药品注册申请，于2025年1月获得受理，并于近日获得国家药监局批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002940","IPOS","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640937633","title":"昂利康(002940.SZ)：子公司异氟烷获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2640937633","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640937633?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:04","pubTimestamp":1780304645,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昂利康(002940.SZ)发布公告，近日，公司子公司福建海西联合药业有限公司收到国家药品监督管理局签发的异氟烷《药品注册证书》。据悉，异氟烷可用于全身麻醉的诱导和维持。此次获得《药品注册证书》视同通过一致性评价，将进一步丰富公司的仿制药产品管线，增强公司的综合竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639673117","title":"昂利康（002940）披露2025年度股东会决议公告，5月29日股价下跌1.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639673117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639673117?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:15","pubTimestamp":1780064124,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，昂利康报收于35.0元，较前一交易日下跌1.41%，最新总市值为70.6亿元。该股当日开盘35.8元，最高36.28元，最低34.52元，成交额达6.07亿元，换手率为9.29%。近日，浙江昂利康制药股份有限公司发布《2025年度股东会决议公告》。公告显示，公司于2026年5月29日召开2025年度股东会，会议审议通过了《2025年度董事会工作报告》《2025年度财务决算报告》《2025年度利润分配预案》《2025年年度报告及摘要》等议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900046210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639629948","title":"昂利康(002940.SZ)：氟伐他汀钠缓释片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2639629948","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639629948?lang=zh_cn&edition=full","pubTime":"2026-05-29 18:18","pubTimestamp":1780049922,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昂利康(002940.SZ)发布公告，近日，公司收到国家药品监督管理局签发的氟伐他汀钠缓释片《药品注册证书》。据悉，氟伐他汀钠缓释片用于饮食未能完全控制的原发性高胆固醇血症和混合型血脂异常(Fredrickson II a及II b型)的患者。根据国家相关政策规定，此次获得《药品注册证书》视同通过一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"昂利康(002940.SZ)：氟伐他汀钠缓释片获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002940","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638687280","title":"股市必读：新发布《浙江昂利康制药股份有限公司与东方证券股份有限公司关于浙江昂利康制药股份有限公司申请向特定对象发行股票的审核问询函的回复》","url":"https://stock-news.laohu8.com/highlight/detail?id=2638687280","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638687280?lang=zh_cn&edition=full","pubTime":"2026-05-28 01:17","pubTimestamp":1779902228,"startTime":"0","endTime":"0","summary":"公司公告汇总浙江昂利康制药股份有限公司于2026年5月26日召开第四届董事会第十九次会议，审议通过关于调整公司2025年度向特定对象发行A股股票方案的议案。本次投资无需提交董事会或股东会审议，不构成关联交易或重大资产重组。业绩披露要点浙江昂利康制药股份有限公司2025年度财务报告经审计，审计意见为标准无保留意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800000959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0239","BK1564","BK1147","002940","BK0183","600958","BK0276","BK0188","BK0028","01477","BK0012","BK1574","03958"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638864816","title":"昂利康（002940）披露2025年度向特定对象发行A股股票预案（二次修订稿），5月27日股价上涨2.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638864816","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638864816?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:13","pubTimestamp":1779891194,"startTime":"0","endTime":"0","summary":"截至2026年5月27日收盘，昂利康报收于36.88元，较前一交易日上涨2.56%，最新总市值为74.4亿元。该股当日开盘35.95元，最高38.99元，最低35.24元，成交额达7.87亿元，换手率为11.34%。近日，浙江昂利康制药股份有限公司披露《2025年度向特定对象发行A股股票预案》。公告显示，公司拟向特定对象发行A股股票，募集资金总额111,000.00万元，用于创新药研发项目。本次发行尚需深交所审核通过及中国证监会同意注册。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700045899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940","399300","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638555378","title":"昂利康（002940）披露股票交易异常波动公告，5月25日股价下跌10.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638555378","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638555378?lang=zh_cn&edition=full","pubTime":"2026-05-25 22:08","pubTimestamp":1779718099,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘，昂利康报收于36.98元，较前一交易日下跌10.0%，最新总市值为74.6亿元。该股当日开盘39.2元，最高39.95元，最低36.98元，成交额达7.67亿元，换手率为10.93%。近日，浙江昂利康制药股份有限公司发布《股票交易异常波动公告》。公告显示，公司股票连续2个交易日收盘价格跌幅偏离值累计超过20%，构成异常波动。公司及控股股东不存在应披露未披露的重大事项，股票交易异常波动期间无买卖行为。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500033922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638553790","title":"昂利康最新公告：公司不涉及光芯片等半导体领域的业务和投资行为","url":"https://stock-news.laohu8.com/highlight/detail?id=2638553790","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638553790?lang=zh_cn&edition=full","pubTime":"2026-05-25 19:21","pubTimestamp":1779708065,"startTime":"0","endTime":"0","summary":"昂利康(002940)公告称，公司股票连续2个交易日(5月22日、25日)收盘价格跌幅偏离值累计超过20%。公司近期关注到有关自媒体、财经股吧等网络平台有个别用户发表涉及“聊聊昂利康，深度挖掘他的逻辑，很可能是光芯片的新玩家”“昂利康实控人体外孵化，新公司对标新易盛源杰”等内容。经公司自查，截止目前，公司不涉及光芯片等半导体领域的业务和投资行为，公司实际控制人吕慧浩及其近亲属仅持有浙江嵊熠光电有限公司（以下简称“嵊熠光电”）部分少数股权，系其及其近亲属的个人对外财务性投资，嵊熠光电与公司不存在业务合作关系。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500027906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159813","159582","002940"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783013894905,"stockEarnings":[{"period":"1week","weight":0.048},{"period":"1month","weight":-0.1197},{"period":"3month","weight":-0.1294},{"period":"6month","weight":-0.1286},{"period":"1year","weight":-0.346},{"period":"ytd","weight":-0.1286}],"compareEarnings":[{"period":"1week","weight":-0.0222},{"period":"1month","weight":-0.0113},{"period":"3month","weight":0.0384},{"period":"6month","weight":0.0151},{"period":"1year","weight":0.1662},{"period":"ytd","weight":0.0151}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江昂利康制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"40232人(较上一季度增加1.85%)","perCapita":"4605股","listingDate":"2018-10-23","address":"浙江省绍兴市嵊州市嵊州大道北1000号","registeredCapital":"20172万元","survey":" 浙江昂利康制药股份有限公司的主营业务是化学原料药、化学制剂及特色中间体系列产品的研发、生产和销售。公司的主要产品是抗感染类、心血管类、泌尿系统类（肾病类）、麻醉疼痛类、抗雄性激素类。","listedPrice":23.07},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昂利康(002940)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昂利康(002940)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昂利康,002940,昂利康股票,昂利康股票老虎,昂利康股票老虎国际,昂利康行情,昂利康股票行情,昂利康股价,昂利康股市,昂利康股票价格,昂利康股票交易,昂利康股票购买,昂利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昂利康(002940)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昂利康(002940)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}